K
Kathryn P. Gray
Researcher at Harvard University
Publications - 81
Citations - 2338
Kathryn P. Gray is an academic researcher from Harvard University. The author has contributed to research in topics: Prostate cancer & Breast cancer. The author has an hindex of 21, co-authored 78 publications receiving 1720 citations. Previous affiliations of Kathryn P. Gray include Boston University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
PD-L1 expression in nonclear-cell renal cell carcinoma
Toni K. Choueiri,Toni K. Choueiri,André P. Fay,Kathryn P. Gray,Marcella Callea,Thai H. Ho,Laurence Albiges,Joaquim Bellmunt,Joaquim Bellmunt,Jiaxi Song,Ingrid Carvo,Megan E. Lampron,Melissa L. Stanton,F.S. Hodi,David F. McDermott,David F. McDermott,Michael B. Atkins,Gordon J. Freeman,Michelle S. Hirsch,Michelle S. Hirsch,Sabina Signoretti,Sabina Signoretti +21 more
TL;DR: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD- L1 positivity in tumor cells is associated with higher tumor stage and grade.
Journal ArticleDOI
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
David J. Kwiatkowski,Toni K. Choueiri,André P. Fay,André P. Fay,Brian I. Rini,Aaron R. Thorner,Guillermo de Velasco,Magdalena E. Tyburczy,Lana Hamieh,Laurence Albiges,Neeraj Agarwal,Thai H. Ho,Jiaxi Song,Jean-Christophe Pignon,Pablo M. Barrios,M. Dror Michaelson,Eliezer M. Van Allen,Katherine M. Krajewski,Camillo Porta,Sumanta K. Pal,Joaquim Bellmunt,David F. McDermott,Daniel Y.C. Heng,Kathryn P. Gray,Sabina Signoretti +24 more
TL;DR: In this cohort of mRCC patients, mutations in MTOR, TSC1, or TSC2 were more common in patients who experienced clinical benefit from rapalogs than in those who progressed, but a substantial fraction of responders had no mTOR pathway mutation identified.
Journal ArticleDOI
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Anis A. Hamid,Kathryn P. Gray,Grace Shaw,Laura E. MacConaill,Laura E. MacConaill,Carolyn Evan,Brandon Bernard,Brandon Bernard,Massimo Loda,Niall M. Corcoran,Eliezer M. Van Allen,Atish D. Choudhury,Christopher Sweeney +12 more
TL;DR: Deleterious TSG variants are associated with an increased risk of relapse (L) and death (M1) in CSPC and these findings help identify patients with aggressive features who may benefit from intensified treatment.
Journal ArticleDOI
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Joyce F. Liu,Christina I. Herold,Kathryn P. Gray,Richard T. Penson,Neil S. Horowitz,Panagiotis A. Konstantinopoulos,Cesar M. Castro,Sarah J. Hill,Jennifer Curtis,Weixiu Luo,Ursula A. Matulonis,Stephen A. Cannistra,Don S. Dizon,Don S. Dizon +13 more
TL;DR: The nivolumab with bevacizumab combination appeared to show activity in patients with relapsed ovarian cancer, with greater activity in the platinum-sensitive setting, and alternative combinational strategies may be necessary in theatinum-resistant setting.
Journal ArticleDOI
Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers
Anieta M. Sieuwerts,Scooter Willis,Michael B. Burns,Maxime P. Look,Marion E. Meijer-van Gelder,Andreas Schlicker,Marinus R. Heideman,Heinz Jacobs,Lodewyk F. A. Wessels,Brian Leyland-Jones,Kathryn P. Gray,John A. Foekens,Reuben S. Harris,John W.M. Martens +13 more
TL;DR: APOBEC3B is a marker of pure prognosis and poor outcomes for ER’s+ breast cancer, which strongly suggests that genetic aberrations induced by APOBec3B contribute to breast cancer progression.